Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment

被引：0
|
作者：
Josep M. Llovet
Arndt Vogel
David C. Madoff
Richard S. Finn
Sadahisa Ogasawara
Zhenggang Ren
Kalgi Mody
Jerry J. Li
Abby B. Siegel
Leonid Dubrovsky
Masatoshi Kudo
机构：
[1] Tisch Cancer Institute,Mount Sinai Liver Cancer Program, Icahn School of Medicine at Mount Sinai
[2] University of Barcelona,Translational Research in Hepatic Oncology, IDIBAPS, Hospital Clinic Barcelona
[3] Institució Catalana d’Estudis Avançats (ICREA),Graduate School of Medicine
[4] Hannover Medical School,School of Medicine
[5] Yale School of Medicine and Yale Cancer Center/Smilow Cancer Hospital,undefined
[6] David Geffen School of Medicine at UCLA,undefined
[7] Chiba University,undefined
[8] Zhongshan Hospital Fudan University,undefined
[9] Eisai Inc,undefined
[10] Merck & Co.,undefined
[11] Inc,undefined
[12] Kindai University,undefined
来源：
CardioVascular and Interventional Radiology | 2022年 / 45卷
关键词：
Intermediate-stage hepatocellular carcinoma; Lenvatinib; Pembrolizumab; Transarterial chemoembolization;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：405 / 412
页数：7
相关论文
共 50 条
  • [41] Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients
    Zhu, Caihua
    Dai, Bing
    Zhan, Hua
    Deng, Ruoyu
    IRISH JOURNAL OF MEDICAL SCIENCE, 2023, 192 (03) : 1065 - 1071
  • [42] Efficacy of sequential transarterial chemoembolization plus percutaneous ethanol injection for the treatment of intermediate stage hepatocellular carcinoma: Results of a pilot study
    Castroagudin, J. F.
    Molina, E.
    Garcia-Vazquez, M.
    Seoane, C.
    Seijo, S.
    Alvarez, A. M.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S141 - S141
  • [43] Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study
    Lu, Linbin
    Shen, Lujun
    Wu, Zhixian
    Shi, Yanhong
    Hou, Peifeng
    Xue, Zengfu
    Lin, Cheng
    Chen, Xiong
    ECLINICALMEDICINE, 2022, 47
  • [44] Efficacy and Safety of Lenvatinib Plus Programmed Death-1 Inhibitors with or Without Transarterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma
    Jin, Ming
    Jiang, Zhi-qing
    Qin, Jia-hui
    Qin, Hui-xia
    Jiang, Kai-wen
    Ya, Hou-xiang
    Gu, Jing
    Gui, Mo-rui
    Li, Yao-hua
    Xu, Long-kuan
    Fu, Hai-xiao
    Xiao, Xu-hua
    Li, Shu-qun
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 2309 - 2320
  • [45] Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: A phase 3, multicenter, randomized controlled trial
    Peng, Zhenwei
    Fan, Wenzhe
    Zhu, Bowen
    Li, Jiaping
    Kuang, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [46] Achievement of Complete Response and Drug-free Status by Atezolizumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-stage Hepatocellular Carcinoma: A Multicenter Proof-of-Concept Study
    Kudo, Masatoshi
    Aoki, Tomoko
    Ueshima, Kazuomi
    Tsuchiya, Kaoru
    Morita, Masahiro
    Chishina, Hirokazu
    Takita, Masahiro
    Hagiwara, Satoru
    Minami, Yasunori
    Ida, Hiroshi
    Nishida, Naoshi
    Ogawa, Chikara
    Tomonari, Tetsu
    Nakamura, Noriaki
    Kuroda, Hidekatsu
    Takebe, Atsushi
    Takeyama, Yoshifumi
    Hidaka, Masaaki
    Eguchi, Susumu
    Chan, Stephen L.
    Kurosaki, Masayuki
    Izumi, Namiki
    LIVER CANCER, 2023, 12 (04) : 321 - 338
  • [47] Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002) a randomised, double-blind, phase 3 trial
    Llovet, Josep M.
    Kudo, Masatoshi
    Merle, Philippe
    Meyer, Tim
    Qin, Shukui
    Ikeda, Masafumi
    Xu, Ruocai
    Edeline, Julien
    Ryoo, Baek-Yeol
    Ren, Zhenggang
    Masi, Gianluca
    Kwiatkowski, Mariusz
    Lim, Ho Yeong
    Kim, Jee Hyun
    Breder, Valeriy
    Kumada, Hiromitsu
    Cheng, Ann-Lii
    Galle, Peter R.
    Kaneko, Shuichi
    Wang, Anran
    Mody, Kalgi
    Dutcus, Corina
    Dubrovsky, Leonid
    Siegel, Abby B.
    Finn, Richard S.
    LANCET ONCOLOGY, 2023, 24 (12): : 1399 - 1410
  • [48] Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis
    Shimose, Shigeo
    Kawaguchi, Takumi
    Tanaka, Masatoshi
    Iwamoto, Hideki
    Miyazaki, Ken
    Moriyama, Etsuko
    Suzuki, Hiroyuki
    Niizeki, Takashi
    Shirono, Tomotake
    Nakano, Masahito
    Suga, Hideya
    Yamaguchi, Taizo
    Yokokura, Yoshinori
    Noguchi, Kazunori
    Koga, Hironori
    Torimura, Takuji
    ONCOLOGY LETTERS, 2020, 20 (03) : 2257 - 2265
  • [49] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [50] Tumor Marker-Based Definition of the Transarterial Chemoembolization-Refractoriness in Intermediate-Stage Hepatocellular Carcinoma: A Multi-Cohort Study
    Yoon, Jun Sik
    Sinn, Dong Hyun
    Lee, Jeong-Hoon
    Kim, Hwi Young
    Lee, Cheol-Hyung
    Kim, Sun Woong
    Lee, Hyo Young
    Nam, Joon Yeul
    Chang, Young
    Lee, Yun Bin
    Cho, Eun Ju
    Yu, Su Jong
    Kim, Hyo-Cheol
    Chung, Jin Wook
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    CANCERS, 2019, 11 (11)
12345